Cannabis Bioscience International Holdings, Inc. (CBIH) EBITDA (2022 - 2026)
Cannabis Bioscience International Holdings (CBIH) posted EBITDA of -$93259.0 for Q1 2026, up 2.73% sequentially from -$95877.0 in Q4 2025, and up 27.84% YoY from -$72951.4 in Q1 2025.
Cannabis Bioscience International Holdings, Inc. (CBIH) EBITDA (2022 - 2026) Analysis & Trends
Cannabis Bioscience International Holdings has reported EBITDA for 5 years, with the latest figure at -$93259.0 in Q1 2026.
- Quarterly EBITDA rose 27.84% year-over-year to -$93259.0 in Q1 2026, while the trailing twelve-month figure through Feb 2026 was -$398820.0 (down 26.17% YoY) and the FY2025 annual result came in at -$421365.0, up 13.32% from the prior year.
- EBITDA improved to -$93259.0 in Q1 2026 per CBIH's latest filing, from -$95877.0 in the prior quarter.
- Over five years, EBITDA peaked at -$29634.0 in Q2 2024 and troughed at -$284866.0 in Q1 2023.
- A 5-year average of -$134968.4 and a median of -$113419.0 in 2024 frame the typical range for EBITDA.
- The sharpest annual moves came in 2024 and 2025: EBITDA soared 89.22% in 2024, then tumbled 355.22% in 2025.
- Over 5 years, EBITDA stood at -$183608.0 in 2022, then soared by 48.53% to -$94512.0 in 2023, then surged by 36.91% to -$59627.0 in 2024, then plunged by 60.79% to -$95877.0 in 2025, then rose by 2.73% to -$93259.0 in 2026.
- According to Business Quant data, EBITDA over the past three periods registered -$93259.0, -$95877.0, and -$74784.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | -93,259.00 |
| Nov 30, 2025 | -95,877.00 |
| Aug 31, 2025 | -74,784.00 |
| May 31, 2025 | -134,900.00 |
| Feb 28, 2025 | -129,234.00 |
| Nov 30, 2024 | -59,627.00 |
| Aug 31, 2024 | -97,604.00 |
| May 31, 2024 | -29,634.00 |
| Feb 29, 2024 | -159,971.00 |
| Nov 30, 2023 | -94,512.00 |
| Aug 31, 2023 | -176,784.00 |
| May 31, 2023 | -274,898.00 |
| Feb 28, 2023 | -284,866.00 |
| Nov 30, 2022 | -183,608.00 |